297 related articles for article (PubMed ID: 35909975)
21. Antibodies to Cryptic Epitopes in Distant Homologues Underpin a Mechanism of Heterologous Immunity between
Mitran CJ; Mena A; Gnidehou S; Banman S; Arango E; Lima BAS; Lugo H; Ganesan A; Salanti A; Mbonye AK; Ntumngia F; Barakat K; Adams JH; Kano FS; Carvalho LH; Maestre AE; Good MF; Yanow SK
mBio; 2019 Oct; 10(5):. PubMed ID: 31594821
[TBL] [Abstract][Full Text] [Related]
22. Non-allele specific antibody responses to genetically distinct variant forms of Plasmodium vivax Duffy binding protein (PvDBP-II) in Iranians exposed to seasonal malaria transmission.
Valizadeh V; Zakeri S; Mehrizi AA; Djadid ND
Acta Trop; 2014 Aug; 136():89-100. PubMed ID: 24704284
[TBL] [Abstract][Full Text] [Related]
23. Strain-specific duffy binding protein antibodies correlate with protection against infection with homologous compared to heterologous plasmodium vivax strains in Papua New Guinean children.
Cole-Tobian JL; Michon P; Biasor M; Richards JS; Beeson JG; Mueller I; King CL
Infect Immun; 2009 Sep; 77(9):4009-17. PubMed ID: 19564376
[TBL] [Abstract][Full Text] [Related]
24. Sequence analysis of Plasmodium vivax Duffy binding proteins reveals the presence of unique haplotypes and diversifying selection in Ethiopian isolates.
Golassa L; Messele A; Oriero EC; Amambua-Ngwa A
Malar J; 2021 Jul; 20(1):312. PubMed ID: 34246262
[TBL] [Abstract][Full Text] [Related]
25. Plasmodium simium, a Plasmodium vivax-related malaria parasite: genetic variability of Duffy binding protein II and the Duffy antigen/receptor for chemokines.
Camargos Costa D; Pereira de Assis GM; de Souza Silva FA; Araújo FC; de Souza Junior JC; Braga Hirano ZM; Satiko Kano F; Nóbrega de Sousa T; Carvalho LH; Ferreira Alves de Brito C
PLoS One; 2015; 10(6):e0131339. PubMed ID: 26107662
[TBL] [Abstract][Full Text] [Related]
26. Naturally Acquired Binding-Inhibitory Antibodies to Plasmodium vivax Duffy Binding Protein and Clinical Immunity to Malaria in Rural Amazonians.
Nicolete VC; Frischmann S; Barbosa S; King CL; Ferreira MU
J Infect Dis; 2016 Nov; 214(10):1539-1546. PubMed ID: 27578850
[TBL] [Abstract][Full Text] [Related]
27. Genetic diversity of Plasmodium vivax Duffy Binding Protein II (PvDBPII) under unstable transmission and low intensity malaria in Sri Lanka.
Premaratne PH; Aravinda BR; Escalante AA; Udagama PV
Infect Genet Evol; 2011 Aug; 11(6):1327-39. PubMed ID: 21554998
[TBL] [Abstract][Full Text] [Related]
28. Fine specificity of Plasmodium vivax Duffy binding protein binding engagement of the Duffy antigen on human erythrocytes.
Siddiqui AA; Xainli J; Schloegel J; Carias L; Ntumngia F; Shoham M; Casey JL; Foley M; Adams JH; King CL
Infect Immun; 2012 Aug; 80(8):2920-8. PubMed ID: 22615246
[TBL] [Abstract][Full Text] [Related]
29. Population genetics and natural selection in the gene encoding the Duffy binding protein II in Iranian Plasmodium vivax wild isolates.
Valizadeh V; Zakeri S; Mehrizi AA; Djadid ND
Infect Genet Evol; 2014 Jan; 21():424-35. PubMed ID: 24384095
[TBL] [Abstract][Full Text] [Related]
30. Broadly neutralizing epitopes in the Plasmodium vivax vaccine candidate Duffy Binding Protein.
Chen E; Salinas ND; Huang Y; Ntumngia F; Plasencia MD; Gross ML; Adams JH; Tolia NH
Proc Natl Acad Sci U S A; 2016 May; 113(22):6277-82. PubMed ID: 27194724
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of the precision of the Plasmodium knowlesi growth inhibition assay for Plasmodium vivax Duffy-binding protein-based malaria vaccine development.
Mertens JE; Rigby CA; Bardelli M; Quinkert D; Hou MM; Diouf A; Silk SE; Chitnis CE; Minassian AM; Moon RW; Long CA; Draper SJ; Miura K
Vaccine; 2024 Jun; 42(16):3621-3629. PubMed ID: 38704253
[TBL] [Abstract][Full Text] [Related]
32. Characterization of inhibitory anti-Duffy binding protein II immunity: approach to Plasmodium vivax vaccine development in Thailand.
Chootong P; Panichakul T; Permmongkol C; Barnes SJ; Udomsangpetch R; Adams JH
PLoS One; 2012; 7(4):e35769. PubMed ID: 22558221
[TBL] [Abstract][Full Text] [Related]
33. Structural basis for neutralization of Plasmodium vivax by naturally acquired human antibodies that target DBP.
Urusova D; Carias L; Huang Y; Nicolete VC; Popovici J; Roesch C; Salinas ND; Dechavanne S; Witkowski B; Ferreira MU; Adams JH; Gross ML; King CL; Tolia NH
Nat Microbiol; 2019 Sep; 4(9):1486-1496. PubMed ID: 31133752
[TBL] [Abstract][Full Text] [Related]
34. Polymorphism patterns in Duffy-binding protein among Thai Plasmodium vivax isolates.
Gosi P; Khusmith S; Khalambaheti T; Lanar DE; Schaecher KE; Fukuda MM; Miller SR
Malar J; 2008 Jun; 7():112. PubMed ID: 18582360
[TBL] [Abstract][Full Text] [Related]
35. Design and immunogenicity of a novel synthetic antigen based on the ligand domain of the Plasmodium vivax duffy binding protein.
Ntumngia FB; Adams JH
Clin Vaccine Immunol; 2012 Jan; 19(1):30-6. PubMed ID: 22116684
[TBL] [Abstract][Full Text] [Related]
36. Genetic diversity and neutral selection in Plasmodium vivax erythrocyte binding protein correlates with patient antigenicity.
Han JH; Cho JS; Ong JJY; Park JH; Nyunt MH; Sutanto E; Trimarsanto H; Petros B; Aseffa A; Getachew S; Sriprawat K; Anstey NM; Grigg MJ; Barber BE; William T; Qi G; Liu Y; Pearson RD; Auburn S; Price RN; Nosten F; Rénia L; Russell B; Han ET
PLoS Negl Trop Dis; 2020 Jul; 14(7):e0008202. PubMed ID: 32645098
[TBL] [Abstract][Full Text] [Related]
37. Genetic variability and natural selection at the ligand domain of the Duffy binding protein in Brazilian Plasmodium vivax populations.
Sousa TN; Tarazona-Santos EM; Wilson DJ; Madureira AP; Falcão PR; Fontes CJ; Gil LH; Ferreira MU; Carvalho LH; Brito CF
Malar J; 2010 Nov; 9():334. PubMed ID: 21092207
[TBL] [Abstract][Full Text] [Related]
38. The association of Duffy binding protein region II polymorphisms and its antigenicity in Plasmodium vivax isolates from Thailand.
Chootong P; McHenry AM; Ntumngia FB; Sattabongkot J; Adams JH
Parasitol Int; 2014 Dec; 63(6):858-64. PubMed ID: 25108177
[TBL] [Abstract][Full Text] [Related]
39. Natural acquired inhibitory antibodies to Plasmodium vivax Duffy binding protein (PvDBP-II) equally block erythrocyte binding of homologous and heterologous expressed PvDBP-II on the surface of COS-7 cells.
Valizadeh V; Zakeri S; Mehrizi AA; Mirkazemi S; Djadid ND
Med Microbiol Immunol; 2016 Feb; 205(1):85-95. PubMed ID: 26243337
[TBL] [Abstract][Full Text] [Related]
40. Immunogenicity of a synthetic vaccine based on Plasmodium vivax Duffy binding protein region II.
Ntumngia FB; Barnes SJ; McHenry AM; George MT; Schloegel J; Adams JH
Clin Vaccine Immunol; 2014 Sep; 21(9):1215-23. PubMed ID: 24964808
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
